Tags

Type your tag names separated by a space and hit enter

Accessibility, availability and affordability of anti-malarials in a rural district in Kenya after implementation of a national subsidy scheme.
Malar J. 2011 Oct 26; 10:316.MJ

Abstract

BACKGROUND

Poor access to prompt and effective treatment for malaria contributes to high mortality and severe morbidity. In Kenya, it is estimated that only 12% of children receive anti-malarials for their fever within 24 hours. The first point of care for many fevers is a local medicine retailer, such as a pharmacy or chemist. The role of the medicine retailer as an important distribution point for malaria medicines has been recognized and several different strategies have been used to improve the services that these retailers provide. Despite these efforts, many mothers still purchase ineffective drugs because they are less expensive than effective artemisinin combination therapy (ACT). One strategy that is being piloted in several countries is an international subsidy targeted at anti-malarials supplied through the retail sector. The goal of this strategy is to make ACT as affordable as ineffective alternatives. The programme, called the Affordable Medicines Facility - malaria was rolled out in Kenya in August 2010.

METHODS

In December 2010, the affordability and accessibility of malaria medicines in a rural district in Kenya were evaluated using a complete census of all public and private facilities, chemists, pharmacists, and other malaria medicine retailers within the Webuye Demographic Surveillance Area. Availability, types, and prices of anti-malarials were assessed. There are 13 public or mission facilities and 97 medicine retailers (registered and unregistered).

RESULTS

The average distance from a home to the nearest public health facility is 2 km, but the average distance to the nearest medicine retailer is half that. Quinine is the most frequently stocked anti-malarial (61% of retailers). More medicine retailers stocked sulphadoxine-pyramethamine (SP; 57%) than ACT (44%). Eleven percent of retailers stocked AMFm subsidized artemether-lumefantrine (AL). No retailers had chloroquine in stock and only five were selling artemisinin monotherapy. The mean price of any brand of AL, the recommended first-line drug in Kenya, was $2.7 USD. Brands purchased under the AMFm programme cost 40% less than non-AMFm brands. Artemisinin monotherapies cost on average more than twice as much as AMFm-brand AL. SP cost only $0.5, a fraction of the price of ACT.

CONCLUSIONS

AMFm-subsidized anti-malarials are considerably less expensive than unsubsidized AL, but the price difference between effective and ineffective therapies is still large.

Authors+Show Affiliations

Duke Global Health Institute, Trent Hall, Durham, North Carolina, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22029829

Citation

Smith, Nathan, et al. "Accessibility, Availability and Affordability of Anti-malarials in a Rural District in Kenya After Implementation of a National Subsidy Scheme." Malaria Journal, vol. 10, 2011, p. 316.
Smith N, Obala A, Simiyu C, et al. Accessibility, availability and affordability of anti-malarials in a rural district in Kenya after implementation of a national subsidy scheme. Malar J. 2011;10:316.
Smith, N., Obala, A., Simiyu, C., Menya, D., Khwa-Otsyula, B., & O'Meara, W. P. (2011). Accessibility, availability and affordability of anti-malarials in a rural district in Kenya after implementation of a national subsidy scheme. Malaria Journal, 10, 316. https://doi.org/10.1186/1475-2875-10-316
Smith N, et al. Accessibility, Availability and Affordability of Anti-malarials in a Rural District in Kenya After Implementation of a National Subsidy Scheme. Malar J. 2011 Oct 26;10:316. PubMed PMID: 22029829.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Accessibility, availability and affordability of anti-malarials in a rural district in Kenya after implementation of a national subsidy scheme. AU - Smith,Nathan, AU - Obala,Andrew, AU - Simiyu,Chrispinus, AU - Menya,Diana, AU - Khwa-Otsyula,Barasa, AU - O'Meara,Wendy Prudhomme, Y1 - 2011/10/26/ PY - 2011/07/21/received PY - 2011/10/26/accepted PY - 2011/10/28/entrez PY - 2011/10/28/pubmed PY - 2012/2/9/medline SP - 316 EP - 316 JF - Malaria journal JO - Malar J VL - 10 N2 - BACKGROUND: Poor access to prompt and effective treatment for malaria contributes to high mortality and severe morbidity. In Kenya, it is estimated that only 12% of children receive anti-malarials for their fever within 24 hours. The first point of care for many fevers is a local medicine retailer, such as a pharmacy or chemist. The role of the medicine retailer as an important distribution point for malaria medicines has been recognized and several different strategies have been used to improve the services that these retailers provide. Despite these efforts, many mothers still purchase ineffective drugs because they are less expensive than effective artemisinin combination therapy (ACT). One strategy that is being piloted in several countries is an international subsidy targeted at anti-malarials supplied through the retail sector. The goal of this strategy is to make ACT as affordable as ineffective alternatives. The programme, called the Affordable Medicines Facility - malaria was rolled out in Kenya in August 2010. METHODS: In December 2010, the affordability and accessibility of malaria medicines in a rural district in Kenya were evaluated using a complete census of all public and private facilities, chemists, pharmacists, and other malaria medicine retailers within the Webuye Demographic Surveillance Area. Availability, types, and prices of anti-malarials were assessed. There are 13 public or mission facilities and 97 medicine retailers (registered and unregistered). RESULTS: The average distance from a home to the nearest public health facility is 2 km, but the average distance to the nearest medicine retailer is half that. Quinine is the most frequently stocked anti-malarial (61% of retailers). More medicine retailers stocked sulphadoxine-pyramethamine (SP; 57%) than ACT (44%). Eleven percent of retailers stocked AMFm subsidized artemether-lumefantrine (AL). No retailers had chloroquine in stock and only five were selling artemisinin monotherapy. The mean price of any brand of AL, the recommended first-line drug in Kenya, was $2.7 USD. Brands purchased under the AMFm programme cost 40% less than non-AMFm brands. Artemisinin monotherapies cost on average more than twice as much as AMFm-brand AL. SP cost only $0.5, a fraction of the price of ACT. CONCLUSIONS: AMFm-subsidized anti-malarials are considerably less expensive than unsubsidized AL, but the price difference between effective and ineffective therapies is still large. SN - 1475-2875 UR - https://www.unboundmedicine.com/medline/citation/22029829/Accessibility_availability_and_affordability_of_anti_malarials_in_a_rural_district_in_Kenya_after_implementation_of_a_national_subsidy_scheme_ L2 - https://malariajournal.biomedcentral.com/articles/10.1186/1475-2875-10-316 DB - PRIME DP - Unbound Medicine ER -